Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome

Journal of Autoimmunity

Volumn 39, Issue 3, 2012, Pages 234-239

  Agmon Levin, Nancy ^a   Kivity, Shaye ^a,b   Tzioufas, Athanasios G ^c   López Hoyos, Marcus ^d   Rozman, Blaz ^e   Efes, Inga ^a   Shapira, Yinon ^a   Shamis, Ari ^f   Amital, Howard ^a   Youinou, Pierre ^a,g   Shoenfeld, Yehuda ^h  

^a Universite de Brest   (France)

^b SHEBA MEDICAL CENTER   (Israel)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f Sheba General Hospital   (Israel)

^g BREST UNIVERSITY HOSPITAL   (France)

^h TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmunity; Lymphoma; Neuropathy; Sj gren's syndrome; Vitamin D

Indexed keywords

VITAMIN D;

ADULT; AGED; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DYSPAREUNIA; FATIGUE; FEMALE; FEVER; FIBROMYALGIA; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALIVARY GLAND DISEASE; SEROLOGY; SJOEGREN SYNDROME; SKIN DISEASE; SPLENOMEGALY; VITAMIN BLOOD LEVEL; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; POLYNEUROPATHIES; SJOGREN'S SYNDROME; VITAMIN D;

EID: 84865365409     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.05.018     Document Type: Article

References (104)

1. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9:A305-A310.
2. Tzioufas A.G., Vlachoyiannopoulos P.G. Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. J Autoimmun 2012.
3. Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 2012.
4. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002, 46:741-747.
5. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
6. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. J Autoimmun 2012.
7. Cruz-Tapias P., Rojas-Villarraga A., Maier-Moore S., Anaya J.M. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2011, 11:281-287.
8. Vacek J.L., Vanga S.R., Good M., Lai S.M., Lakkireddy D., Howard P.A. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol 2012, 109:359-363.
9. Salehin D., Haugk C., Thill M., Cordes T., Hornung D., Abu-Hechle A., et al. Serum 25-hydroxyvitamin D levels in patients with vulvar cancer. Anticancer Res 2012, 32:265-270.
10. Yamaji T., Iwasaki M., Sasazuki S., Sakamoto H., Yoshida T., Tsugane S. Association between plasma 25-hydroxyvitamin D and colorectal adenoma according to dietary calcium intake and vitamin D receptor polymorphism. Am J Epidemiol 2012, 175:236-244.
11. Baynes K.C., Boucher B.J., Feskens E.J., Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997, 40:344-347.
12. Schottker B., Ball D., Gellert C., Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2012.
13. Ritterhouse L.L., Crowe S.R., Niewold T.B., Kamen D.L., Macwana S.R., Roberts V.C., et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1569-1574.
14. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164:2405-2411.
15. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
16. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
17. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004, 50:72-77.
18. Cutolo M., Pizzorni C., Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011, 11:84-87.
19. Kivity S., Agmon-Levin N., Zisappl M., Shapira Y., Nagy E.V., Danko K., et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011, 8:243-247.
20. Twig G., Shina A., Amital H., Shoenfeld Y. Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 2012, 38:J275-J281.
21. Hajas A., Sandor J., Csathy L., Csipo I., Barath S., Paragh G., et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011, 10:317-324.
22. Huisman A.M., White K.P., Algra A., Harth M., Vieth R., Jacobs J.W., et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001, 28:2535-2539.
23. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
24. Ben-Zvi I., Aranow C., Mackay M., Stanevsky A., Kamen D.L., Marinescu L.M., et al. The impact of vitamin d on dendritic cell function in patients with systemic lupus erythematosus. PLoS One 2010, 5:e9193.
25. Agmon-Levin N., Blank M., Zandman-Goddard G., Orbach H., Meroni P.L., Tincani A., et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011, 70:145-150.
26. Arnson Y., Amital H., Agmon-Levin N., Alon D., Sanchez-Castanon M., Lopez-Hoyos M., et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011, 10:490-494.
27. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007, 61:504-513.
28. Dahlquist G., Mustonen L. Childhood onset diabetes - time trends and climatological factors. Int J Epidemiol 1994, 23:1234-1241.
29. Mathieu C., Laureys J., Sobis H., Vandeputte M., Waer M., Bouillon R. 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992, 41:1491-1495.
30. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999, 17:453-456.
31. Myhr K.M. Vitamin D treatment in multiple sclerosis. J Neurol Sci 2009, 286:104-108.
32. Huckins D., Felson D.T., Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990, 33:1723-1727.
33. Szodoray P., Horvath I.F., Papp G., Barath S., Gyimesi E., Csathy L., et al. The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren's syndrome. Rheumatology (Oxf) 2010, 49:211-217.
34. Muller K., Oxholm P., Sorensen O.H., Thymann M., Hoier-Madsen M., Bendtzen K. Abnormal vitamin D3 metabolism in patients with primary Sjogren's syndrome. Ann Rheum Dis 1990, 49:682-684.
35. Bang B., Asmussen K., Sorensen O.H., Oxholm P. Reduced 25-hydroxyvitamin D levels in primary Sjogren's syndrome. Correlations to disease manifestations. Scand J Rheumatol 1999, 28:180-183.
36. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
37. Rosen C.J., Gallagher J.C. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011, 14:79-84.
38. Lerner A., Shapira Y., Agmon-Levin N., Pacht A., Ben-Ami Shor D., Lopez H.M., et al. The clinical Significance of 25OH-vitamin D status in celiac disease. Clin Rev Allergy Immunol 2011.
39. Alvarez-Rodriguez L., Lopez-Hoyos M., Garcia-Unzueta M., Amado J.A., Cacho P.M., Martinez-Taboada V.M. Age and low levels of circulating vitamin D are associated with impaired innate immune function. J Leukoc Biol 2012.
40. Baker M.R., Peacock M., Nordin B.E. The decline in vitamin D status with age. Age Ageing 1980, 9:249-252.
41. Arabi A., Baddoura R., El-Rassi R., El-Hajj Fuleihan G. Age but not gender modulates the relationship between PTH and vitamin D. Bone 2010, 47:408-412.
42. Amital H., Szekanecz Z., Szucs G., Danko K., Nagy E., Csepany T., et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010, 69:1155-1157.
43. Pavlakis P.P., Alexopoulos H., Kosmidis M.L., Mamali I., Moutsopoulos H.M., Tzioufas A.G., et al. Peripheral neuropathies in Sjogren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012.
44. Kiraly S.J., Kiraly M.A., Hawe R.D., Makhani N. Vitamin D as a neuroactive substance: review. ScientificWorldJournal 2006, 6:125-139.
45. Chabas J.F., Alluin O., Rao G., Garcia S., Lavaut M.N., Risso J.J., et al. Vitamin D2 potentiates axon regeneration. J Neurotrauma 2008, 25:1247-1256.
46. Turner M.K., Hooten W.M., Schmidt J.E., Kerkvliet J.L., Townsend C.O., Bruce B.K. Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. Pain Med 2008, 9:979-984.
47. Skalli S., Muller M., Pradines S., Halimi S., Wion-Barbot N. Vitamin D deficiency and peripheral diabetic neuropathy. Eur J Intern Med 2012, 23:e67-e68.
48. Valensi P., Le Devehat C., Richard J.L., Farez C., Khodabandehlou T., Rosenbloom R.A., et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications 2005, 19:247-253.
49. Lee P., Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med 2008, 168:771-772.
50. Mackay I.R., Rose N.R. Autoimmunity and lymphoma: tribulations of B cells. Nat Immunol 2001, 2:793-795.
51. Smedby K.E., Baecklund E., Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006, 15:2069-2077.
52. Peri Y., Agmon-Levin N., Theodor E., Shoenfeld Y. Sjogren's syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012, 26:105-117.
53. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
54. Polesel J., Talamini R., Montella M., Parpinel M., Dal Maso L., Crispo A., et al. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. Ann Oncol 2006, 17:713-718.
55. Kelly J.L., Friedberg J.W., Calvi L.M., van Wijngaarden E., Fisher S.G. Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest 2009, 27:942-951.
56. Hickish T., Cunningham D., Colston K., Millar B.C., Sandle J., Mackay A.G., et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 1993, 68:668-672.
57. Raina V., Cunningham D., Gilchrist N., Soukop M. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer 1991, 63:463-465.
58. Kricker A., Armstrong B.K., Hughes A.M., Goumas C., Smedby K.E., Zheng T., et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer 2008, 122:144-154.
59. Hartge P., Lim U., Freedman D.M., Colt J.S., Cerhan J.R., Cozen W., et al. Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control 2006, 17:1045-1052.
60. Chang E.T., Canchola A.J., Cockburn M., Lu Y., Wang S.S., Bernstein L., et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood 2011, 118:1591-1599.
61. Bertrand K.A., Chang E.T., Abel G.A., Zhang S.M., Spiegelman D., Qureshi A.A., et al. Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control 2011, 22:1731-1741.
62. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. J Autoimmun 2011, 37:59-62.
63. Rose N.R. The genetics of autoimmune thyroiditis: the first decade. J Autoimmun 2011, 37:88-94.
64. Youinou P., Haralampos M. Moutsopoulos: a lifetime in autoimmunity. J Autoimmun 2010, 35:171-175.
65. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
66. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2009, 9:A330-A334.
67. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
68. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis [corrected]. Autoimmun Rev 2010, 9:A383-A386.
69. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
70. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
71. Hemminki K., Li X., Sundquist J., Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010, 34:J307-J313.
72. Hoffmann M.H., Trembleau S., Muller S., Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010, 34:J178-J206.
73. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:A355-A365.
74. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
75. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
76. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
77. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34:J220-J225.
78. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010, 9:A247-A250.
79. Chen M., Kallenberg C.G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010, 9:A293-A298.
80. Bhat A., Naguwa S., Cheema G., Gershwin M.E. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
81. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
82. Deane S., Teuber S.S., Gershwin M.E. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010, 9:A342-A349.
83. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
84. Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010, 34:J300-J306.
85. Lambert J.F., Nydegger U.E. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010, 9:A350-A354.
86. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
87. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9:A319-A324.
88. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-J246.
89. Leung P.S., Shu S.A., Kenny T.P., Wu P.Y., Tao M.H. Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 2010, 9:A400-A405.
90. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:A267-A270.
91. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
92. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010, 9:A271-A276.
93. Sands J., Tuscano J.M. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 2010, 9:A335-A341.
94. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371.
95. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010, 9:A288-A292.
96. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010, 34:J322-J326.
97. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
98. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
99. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
100. Mackay I.R. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 2010, 9:A251-A258.
101. Maverakis E., Miyamura Y., Bowen M.P., Correa G., Ono Y., Goodarzi H. Light, including ultraviolet. J Autoimmun 2010, 34:J247-J257.
102. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:A387-A394.
103. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
104. Zeki A.A., Schivo M., Chan A.L., Hardin K.A., Kenyon N.J., Albertson T.E., et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010, 34:J327-J338.